MYCARTIS N V has a total of 28 patent applications. It decreased the IP activity by 100.0%. Its first patent ever was published in 2001. It filed its patents most often in EPO (European Patent Office), WIPO (World Intellectual Property Organization) and Australia. Its main competitors in its focus markets measurement, chemical engineering and biotechnology are SLS MICRO TECHNOLOGY GMBH, SGT EXPLOITATIE BV and SUPERNOVA DIAGNOSTICS INC.
# | Country | Total Patents | |
---|---|---|---|
#1 | EPO (European Patent Office) | 17 | |
#2 | WIPO (World Intellectual Property Organization) | 4 | |
#3 | Australia | 3 | |
#4 | United States | 2 | |
#5 | China | 1 | |
#6 | South Africa | 1 |
# | Industry | |
---|---|---|
#1 | Measurement | |
#2 | Chemical engineering | |
#3 | Biotechnology | |
#4 | Pharmaceuticals | |
#5 | Machines | |
#6 | Audio-visual technology | |
#7 | Organic fine chemistry |
# | Name | Total Patents |
---|---|---|
#1 | Falconnet Didier | 9 |
#2 | Rebetez David | 6 |
#3 | Bernasconi David | 6 |
#4 | Gaillard Mathieu | 6 |
#5 | Kas Koen | 6 |
#6 | Moerman Piet | 5 |
#7 | Gil José | 5 |
#8 | Arrigo Mattia | 4 |
#9 | Thomas Gregoire | 4 |
#10 | Tuytten Robin | 4 |
Publication | Filing date | Title |
---|---|---|
WO2018065417A1 | Method for measuring avidity or functional affinity | |
EP3512633A1 | Prefilled cartridge | |
AU2016347740A1 | Use of CD146 as a marker of the vascular wall tension | |
EP3147650A1 | Cross-talk correction in multiplexing analysis of biological sample | |
EP3036033A1 | Heterogenous surface functionalization | |
EP2491400A1 | Biomarker for diagnosis, prediction and/or prognosis of acute heart failure and uses thereof | |
EP1903337A1 | Coating for microcarriers |